JP2018504112A5 - - Google Patents

Download PDF

Info

Publication number
JP2018504112A5
JP2018504112A5 JP2017536271A JP2017536271A JP2018504112A5 JP 2018504112 A5 JP2018504112 A5 JP 2018504112A5 JP 2017536271 A JP2017536271 A JP 2017536271A JP 2017536271 A JP2017536271 A JP 2017536271A JP 2018504112 A5 JP2018504112 A5 JP 2018504112A5
Authority
JP
Japan
Prior art keywords
seq
polypeptide
cxcr4
sequence
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017536271A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018504112A (ja
JP6863897B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2016/050005 external-priority patent/WO2016109872A1/en
Publication of JP2018504112A publication Critical patent/JP2018504112A/ja
Publication of JP2018504112A5 publication Critical patent/JP2018504112A5/ja
Application granted granted Critical
Publication of JP6863897B2 publication Critical patent/JP6863897B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017536271A 2015-01-09 2016-01-08 Ｃｘｃｒ４結合分子 Active JP6863897B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015900054 2015-01-09
AU2015900054A AU2015900054A0 (en) 2015-01-09 CXCR4 binding molecules
PCT/AU2016/050005 WO2016109872A1 (en) 2015-01-09 2016-01-08 Cxcr4 binding molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020121974A Division JP7212009B2 (ja) 2015-01-09 2020-07-16 Ｃｘｃｒ４結合分子

Publications (3)

Publication Number Publication Date
JP2018504112A JP2018504112A (ja) 2018-02-15
JP2018504112A5 true JP2018504112A5 (enExample) 2019-11-14
JP6863897B2 JP6863897B2 (ja) 2021-04-21

Family

ID=56355354

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017536271A Active JP6863897B2 (ja) 2015-01-09 2016-01-08 Ｃｘｃｒ４結合分子
JP2020121974A Active JP7212009B2 (ja) 2015-01-09 2020-07-16 Ｃｘｃｒ４結合分子
JP2022181132A Pending JP2023015277A (ja) 2015-01-09 2022-11-11 Ｃｘｃｒ４結合分子

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020121974A Active JP7212009B2 (ja) 2015-01-09 2020-07-16 Ｃｘｃｒ４結合分子
JP2022181132A Pending JP2023015277A (ja) 2015-01-09 2022-11-11 Ｃｘｃｒ４結合分子

Country Status (11)

Country Link
US (2) US10538596B2 (enExample)
EP (2) EP3242685B1 (enExample)
JP (3) JP6863897B2 (enExample)
CN (2) CN107427574B (enExample)
AU (3) AU2016206191B2 (enExample)
DK (1) DK3242685T3 (enExample)
ES (1) ES2924394T3 (enExample)
HR (1) HRP20220860T1 (enExample)
LT (1) LT3242685T (enExample)
SG (2) SG10202111844VA (enExample)
WO (1) WO2016109872A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3242685B1 (en) * 2015-01-09 2022-05-04 AdAlta Limited Cxcr4 binding molecules
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
JP7258762B2 (ja) 2016-11-07 2023-04-17 デーゲンエルイックス べスローテン フェンノートシャップ 新規アミロイドベータオリゴマー特異的結合分子
WO2018130702A1 (en) * 2017-01-16 2018-07-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Improved multi tyrosine kinase inhibitor therapy
US10709763B2 (en) * 2017-12-19 2020-07-14 Gpcr Therapeutics, Inc. GPCR heteromer inhibitors and uses thereof
WO2020205836A1 (en) * 2019-04-02 2020-10-08 Eli Lilly And Company Methods of selecting and detecting binding peptides
EP3969007A4 (en) * 2019-05-17 2023-06-07 GPCR Therapeutics, Inc. GPCR HETEROMERIC INHIBITORS AND THEIR USES
JP7365674B2 (ja) * 2019-08-29 2023-10-20 国立大学法人 長崎大学 アスペルギローマモデル非ヒト動物
CN110804100A (zh) * 2019-11-01 2020-02-18 中国人民解放军陆军特色医学中心 融合多肽及其在增强干细胞归巢能力和抗凋亡能力中的应用和药物组合物
JP2023518000A (ja) * 2020-03-13 2023-04-27 ユリウス－マクシミリアン－ウニヴェルシテート・ヴュルツブルク Ｒｏｒ２をターゲティングする、親和性成熟ヒト化結合性ドメイン
US20250297020A1 (en) * 2021-11-23 2025-09-25 Adalta Limited Rank-l binding molecules
CN114533884A (zh) * 2022-04-20 2022-05-27 澳门大学 一种联合治疗癌症的药物及s100a9-cxcl12信号抑制剂的应用
JP2023172979A (ja) * 2022-05-24 2023-12-07 国立大学法人京都大学 ポリペプチド
CN121969930A (zh) * 2023-07-07 2026-05-01 阿达尔塔有限公司 将受体占有率与cxcr4拮抗剂功效相关联

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4439A (en) 1846-04-04 Improvement in cleansing fish-oils
US4475A (en) 1846-04-25 Henry johnson
US196A (en) 1837-05-15 Machine for mowing and heaping grain
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US5206154A (en) 1985-01-28 1993-04-27 Xoma Corporation Method of producing cecropins by microbiological techniques
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5215896A (en) 1987-03-20 1993-06-01 Creative Biomolecules, Inc. Leader sequences for the production of recombinant proteins
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
SE8804074D0 (sv) 1988-11-10 1988-11-10 Pharmacia Ab Sensorenhet och dess anvaendning i biosensorsystem
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
JPH08501213A (ja) 1992-08-21 1996-02-13 ザ ユニバーシティー オブ ブリティッシュ コロンビア カチオン性ペプチド及びその製造方法
US5648244A (en) 1993-09-27 1997-07-15 President And Fellows Of Harvard College Production, purification, cleavage and use of fusion peptides
US5485277A (en) 1994-07-26 1996-01-16 Physical Optics Corporation Surface plasmon resonance sensor and methods for the utilization thereof
US6037145A (en) 1994-09-07 2000-03-14 Suntory Limited Process for production of protein
US5567301A (en) 1995-03-01 1996-10-22 Illinois Institute Of Technology Antibody covalently bound film immunobiosensor
US5972639A (en) 1997-07-24 1999-10-26 Irori Fluorescence-based assays for measuring cell proliferation
DE19818790A1 (de) 1998-04-27 1999-10-28 Affina Immuntechnik Gmbh Immunadsorptionsmatrix, Verfahren zu ihrer Herstellung und ihre Verwendung
BRPI9910332B8 (pt) 1998-05-06 2021-05-25 Genentech Inc método para purificação de um polipeptídio a partir de uma composição
AU5220099A (en) 1998-07-31 2000-02-21 Pierce Chemical Company Fusion products containing insoluble proteinaceous tag
US6190908B1 (en) 1998-08-12 2001-02-20 The Scripps Research Institute Modulation of polypeptide display on modified filamentous phage
US6306610B1 (en) 1998-09-18 2001-10-23 Massachusetts Institute Of Technology Biological applications of quantum dots
US6242219B1 (en) 1999-03-18 2001-06-05 Xoma (Us) Llc Methods for recombinant peptide production
WO2001002551A2 (en) 1999-06-30 2001-01-11 Evotec Oai Ag Virus like particles, preparation and use in screening and functional genomics
US20060228364A1 (en) 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
EP1305623A2 (en) 2000-04-25 2003-05-02 Chemicon International Cell proliferation assay
AU2002220577A1 (en) 2000-09-28 2002-04-08 Affina Immuntechnik Gmbh Circulatory device for separating substances in bodily fluids, especially blood,and the use of said device
EP1532261B1 (en) 2002-05-24 2010-02-10 Medtronic, Inc. Methods and dna constructs for high yield production of polypeptides
US8574590B2 (en) 2003-07-30 2013-11-05 Integral Molecular, Inc. Lipoparticles comprising proteins, methods of making, and using the same
US20080299042A1 (en) * 2004-04-30 2008-12-04 Biogen Idec Ma Inc. Membrane Associated Molecules
US8921528B2 (en) 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
DK2330121T3 (en) * 2004-06-02 2014-12-15 Adalta Pty Ltd Binding moieties based on shark IgNar domains
US7807704B2 (en) 2006-03-30 2010-10-05 Chemocentryx, Inc. Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2
WO2007115232A2 (en) 2006-03-30 2007-10-11 Chemocentryx, Inc. Cxcr4 modulators
ES2625798T3 (es) * 2006-10-02 2017-07-20 E. R. Squibb & Sons, L.L.C. Anticuerpos humanos que se unen a CXCR4 y usos de los mismos
US8088895B2 (en) 2006-10-18 2012-01-03 Chemocentryx, Inc. Antibodies that bind CXCR7 epitopes
WO2008055313A1 (en) 2006-11-10 2008-05-15 Dimerix Bioscience Pty Ltd Detection system and uses therefor
WO2008109154A1 (en) 2007-03-08 2008-09-12 Altiris Therapeutics, Inc. Chemokine receptor modulators
WO2009117710A2 (en) 2008-03-20 2009-09-24 Carolus Therapeutics, Inc. Methods of treating inflammation
US20100092470A1 (en) * 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
CN102271681B (zh) 2008-11-04 2014-11-12 凯莫森特里克斯股份有限公司 Cxcr7调节剂
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
SI2776032T1 (sl) * 2011-11-09 2018-12-31 Bristol-Myers Squibb Company Zdravljenje hematoloških malignih obolenj z anti-CXCR4 protitelesom
US20160031937A1 (en) * 2013-03-08 2016-02-04 Curonz Holdings Company Limited Neural regeneration peptides and uses therefor
EP3242685B1 (en) 2015-01-09 2022-05-04 AdAlta Limited Cxcr4 binding molecules

Similar Documents

Publication Publication Date Title
AU2024264558B2 (en) Bicyclic peptide ligands specific for Nectin-4
TW496870B (en) Compositions methods for stimulating megakaryocyte growth and differentiation
JP2022105138A5 (enExample)
JP2023505492A5 (enExample)
JP2021522175A5 (enExample)
ES2199941T3 (es) Anticuerpos monoclonales contra el receptor de la interferona, con actividad neutralizadora contra el interferon de tipo j.
JP2019506841A5 (enExample)
HRP20220865T1 (hr) T stanični receptori
JP2019511222A5 (enExample)
HRP20220860T1 (hr) Cxcr4 vezujuće molekule
JP2017079785A5 (enExample)
JP2018522563A5 (enExample)
JP2019513764A5 (enExample)
RU2016101711A (ru) Высокостабильный т-клеточный рецептор и способ его получения и применения
JP2021502980A5 (enExample)
JP2017522903A5 (enExample)
BRPI0706788A2 (pt) anticorpos antagonistas il-17
JP2020503262A5 (ja) アクチビンＩＩａ型受容体変異体および同変異体を含む医薬組成物
TW200531979A (en) Inhibitors of type 2 vascular endothelial growth factor receptors
JP2015522576A5 (enExample)
ES2926511T3 (es) Anticuerpos anti-CLEVER-1 humanizados y utilización de los mismos
JP2011502479A5 (enExample)
JPWO2019107530A5 (enExample)
JP2023538422A5 (enExample)
JP2006506942A5 (enExample)